- Home
- CGTX vs ENLV Comparison
CGTX vs ENLV Comparison
Compare CGTX & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGTX
- ENLV
- Stock Information
- Founded
- CGTX 2007
- ENLV 2005
- Country
- CGTX United States
- ENLV Israel
- Employees
- CGTX N/A
- ENLV N/A
- Industry
- CGTX Biotechnology: Pharmaceutical Preparations
- ENLV Biotechnology: Pharmaceutical Preparations
- Sector
- CGTX Health Care
- ENLV Health Care
- Exchange
- CGTX Nasdaq
- ENLV Nasdaq
- Market Cap
- CGTX 23.1M
- ENLV 20.7M
- IPO Year
- CGTX 2021
- ENLV 1995
- Fundamental
- Price
- CGTX $0.31
- ENLV $1.05
- Analyst Decision
- CGTX Strong Buy
- ENLV Strong Buy
- Analyst Count
- CGTX 5
- ENLV 2
- Target Price
- CGTX $6.13
- ENLV $10.00
- AVG Volume (30 Days)
- CGTX 692.0K
- ENLV 51.4K
- Earning Date
- CGTX 05-07-2025
- ENLV 06-13-2025
- Dividend Yield
- CGTX N/A
- ENLV N/A
- EPS Growth
- CGTX N/A
- ENLV N/A
- EPS
- CGTX N/A
- ENLV N/A
- Revenue
- CGTX N/A
- ENLV N/A
- Revenue This Year
- CGTX N/A
- ENLV N/A
- Revenue Next Year
- CGTX N/A
- ENLV N/A
- P/E Ratio
- CGTX N/A
- ENLV N/A
- Revenue Growth
- CGTX N/A
- ENLV N/A
- 52 Week Low
- CGTX $0.31
- ENLV $0.81
- 52 Week High
- CGTX $2.95
- ENLV $1.76
- Technical
- Relative Strength Index (RSI)
- CGTX 31.37
- ENLV 60.60
- Support Level
- CGTX $0.40
- ENLV $1.03
- Resistance Level
- CGTX $0.47
- ENLV $1.15
- Average True Range (ATR)
- CGTX 0.03
- ENLV 0.06
- MACD
- CGTX -0.01
- ENLV 0.02
- Stochastic Oscillator
- CGTX 2.76
- ENLV 77.62
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.
About ENLV Enlivex Therapeutics Ltd.
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.